80 results
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
, immunostimulatory ADCs, dual conjugate ADCs and cytokine derivatives. Our molecules are directed primarily against clinically validated targets where the current … ADCs, or iADCs, dual conjugate ADCs, or ADC2s, and cytokine derivatives. Our molecules are directed primarily against clinically validated targets where
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
-drug conjugate, completing the final stages of pre-clinical development
»STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC … ) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including
424B5
4xi1hj9q7cs gb
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
7s4ot6 glqy8a
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
ai83 udv9md2j882n
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
4f8gyctyc gxvs7fi
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
wn2st
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
q7u0rs4d4i97kiy6
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
lli7e k0n0rzfrn4r
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm
8-K
EX-99.1
fe7vndv q1dnovx6g4o
8 Nov 22
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm